DXCM Price Prediction Next Week
Technical Analysis: DXCM shows a bearish trend in the short term, with the stock closing at $88.78 on February 21, 2025 . The stock has been experiencing downward pressure, trading below its recent highs.
News Sentiment Analysis:
- Positive: DexCom outperformed competitors with a 5.92% rally to $89.07 on February 14
- Mixed: Q4 2024 revenue beat expectations at $1.114 billion, but EPS missed estimates at $0.45 vs $0.50 expected
- Cautious: Analysts note competitive pressures from Abbott and Medtronic could impact expansion
Analyst Consensus:
- Morgan Stanley raised price target from $75 to $82
- Canaccord Genuity maintains Buy rating with increased target from $99 to $103
- Strong Buy consensus with average price target of $101.65, suggesting 14.7% upside
Price Prediction for Next Week (Feb 24-28, 2025): Based on technical indicators and recent news:
- Support level: $87.50
- Resistance level: $90.00
- Target price range: $86-92
Expected price movement:
- Monday: Initial weakness to $87.80
- Mid-week: Consolidation around $88.50
- End of week: Potential recovery to $89.50
Recommendation: HOLD The stock shows mixed signals with strong analyst support but near-term technical weakness. Current price levels suggest limited downside risk, but immediate catalysts for significant upside are lacking. Better entry points may emerge below $87.50.
DXCM Similar Chart Price Prediction
The price of DXCM is predicted to go up 9.37%, based on the high correlation periods with IRT. The similarity of these two price pattern on the periods is 96.27%.
DXCM
IRT
Up: 9.37%Similarity: 96.27%
DXCM Revenue Forecast
DXCM EPS Forecast
DXCM FAQs
What is bull’s view on DXCM?
What is bear's view on DXCM?
What is DXCM revenue forecast for next quarter？
What is DXCM eps forecast for next quarter？
DXCM VS S&P500
Dexcom's next-gen G7 product should be significantly less expensive, offer a thinner profile, and faster warm-up time than G6.
Medicare's decision to reimburse for the G6 is a favorable development for Dexcom, as private payers often use Medicare as the benchmark for reimbursement policies.
Dexcom's initiative with Verily offers the potential to apply tech expertise in data analytics with data-intensive health management for type 2 diabetic patients. This partnership could put Dexcom a step ahead of rivals.
DXCM Analyst's Forecast
William Plovanic
Canaccord Genuity
Strong Buy
2025-02-14
Price Target
$99 → $103
Upside
+15.64%
Canaccord analyst William Plovanic raised the firm's price target on DexCom to $103 from $99 and keeps a Buy rating on the shares. The firm said both US and OUS revenues were ahead of estimates from prior to the preannouncement, with US revenue growing as the company's realigned salesforce continues to improve its productivity following the turmoil of the Q2/24 miss.
Jeff Johnson
Baird
Hold → Buy
2025-01-16
Price Target
$86 → $104
Upside
+22.58%
Joanne Wuensch
Citigroup
Strong Buy
2024-12-11
Price Target
$85 → $91
Upside
+13.09%
